Get Live Data

The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. Hutchmed Share Price
  4. Hutchmed Share News
  5. UK Earnings, Trading Statements Calendar - Next 7 Days

Pin to quick picksHutchmed Share News (HCM)

Hutchmed Information

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 311.00
High: 314.00
Low: 303.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Earnings, Trading Statements Calendar - Next 7 Days

Thu, 25th Feb 2021 16:19

Friday 26 February 
ASA International Group PLCTrading Statement
FBD Holdings PLCFull Year Results
Glenveagh Properties PLCFull Year Results
IMI PLCFull Year Results
International Consolidated Airlines Group SAFull Year Results
Law Debenture Corporation PLCFull Year Results
Revolution Bars Group PLCHalf Year Results
Rightmove PLCFull Year Results
RSA Insurance Group PLCFull Year Results
VR Education Holdings PLCFull Year Results
Avation PLCFull Year Results
Monday 1 March 
AFC Energy PLCFull Year Results
Aggreko PLCFull Year Results
Bank of Ireland Group PLCFull Year Results
Bunzl PLCFull Year Results
CentralNic Group PLCFull Year Results
Craneware PLCHalf Year Results
GlobalData PLCFull Year Results
Greencoat Renewables PLCFull Year Results
Medica Group PLCFull Year Results
Mpac Group PLCFull Year Results
Quartix Holdings PLCFull Year Results
Reach PLCFull Year Results
Seplat Petroleum Development Co PLCFull Year Results
Tuesday 2 March 
Apax Global Alpha LtdFull Year Results
Ashtead Group PLCQ3 Results
Bluefield Solar Income Fund LtdHalf Year Results
Croda International PLCFull Year Results
Devro PLCFull Year Results
Flutter Entertainment PLCFull Year Results
Foxtons Group PLCFull Year Results
Fresnillo PLCFull Year Results
Hotel Chocolat Group PLCHalf Year Results
Intertek Group PLCFull Year Results
James Fisher & Sons PLCFull Year Results
PPHE Hotel Group LtdFull Year Results
Renalytix AI PLCHalf Year Results
Robert Walters PLCFull Year Results
Rotork PLCFull Year Results
Signature Aviation PLCFull Year Results
Supermarket Income REIT PLCHalf Year Results
Taylor Wimpey PLCFull Year Results
Travis Perkins PLCFull Year Results
Uniphar PLCFull Year Results
Weir Group PLCFull Year Results
XP Power LtdFull Year Results
Wednesday 3 March 
Avast PLCFull Year Results
Biffa PLCTrading Statement
GetBusy PLCFull Year Results
Hiscox LtdFull Year Results
International Personal Finance PLCFull Year Results
Nichols PLCFull Year Results
PageGroup PLCFull Year Results
Persimmon PLCFull Year Results
Polymetal International PLCFull Year Results
Prudential PLCFull Year Results
Vivo Energy PLCFull Year Results
Thursday 4 March 
Aviva PLCFull Year Results
Admiral Group PLCFull Year Results
Capital & Regional PLCFull Year Results
Coats Group PLCFull Year Results
CRH PLCFull Year Results
Entain PLCFull Year Results
Franchise Brands PLCFull Year Results
Galliford Try Holdings PLCHalf Year Results
Hunting PLCFull Year Results
Hutchison China MediTech LtdFull Year Results
John Laing Group plcFull Year Results
Meggitt PLCFull Year Results
Melrose Industries PLCFull Year Results
Morgan Advanced Materials PLCFull Year Results
Rathbone Brothers PLCFull Year Results
Rentokil Initial PLCFull Year Results
Schroders PLCFull Year Results
Spire Healthcare Group PLCFull Year Results
Synthomer PLCFull Year Results
Tyman PLCFull Year Results
Vesuvius PLCFull Year Results
Vistry Group PLCFull Year Results
William Hill PLCFull Year Results
  
Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
30 Jan 2024 10:32

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Read more
30 Jan 2024 09:20

Hutchmed celebrates cancer drug approval in hometown of Hong Kong

(Alliance News) - Hutchmed (China) Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marketing approval in the city.

Read more
11 Jan 2024 11:11

Hutchmed application for thrombocytopenia treatment accepted in China

(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted priority review by China's National Medical Products Administration (NMPA).

Read more
11 Jan 2024 10:17

TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau

(Alliance News) - Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country's national bureau for drug supervision.

Read more
21 Dec 2023 11:36

IN BRIEF: Hutchmed China renews deals with "substantial" shareholders

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Agrees with "substantial shareholder" Sinopharm Group Co Ltd to renew the Framework Sinopharm Products Supply & Purchase Agreement, effective from January 1, for three years up to and including December 31, 2026. Also agrees with HCMH to renew the HBYS Brand License Royalty agreement, also effective from January 1 and for the same duration. HCMH entered the HBYS deal in June 2021 with HWEL, a subsidiary of major shareholder CK Hutchison Holdings Ltd which holds an approximate 38.18% stake in Hutchmed.

Read more
13 Dec 2023 13:56

Hutchmed completes enrolment for fruquintinib trial

(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
9 Nov 2023 12:16

Hutchmed hails Takeda's fruquintinib approval from US for cancer form

(Alliance News) - Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has received US approval of fruquintinib for a form of colorectal cancer.

Read more
29 Sep 2023 10:57

Hutchmed confirms new drug application for fruquintinib in Japan

(Sharecast News) - Hutchmed China announced on Friday that its partner Takeda has officially submitted a new drug application (NDA) for fruquintinib to the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Read more
29 Sep 2023 10:12

Hutchmed notes Takeda submits fruquintinib drug application in Japan

(Alliance News) - Hutchmed (China) Ltd on Friday said Takeda Pharmaceutical Co Ltd has submitted a new drug application for cancer treatment fruquintinib to the Ministry of Health, Labour & Welfare in Japan.

Read more
14 Sep 2023 13:09

Director dealings: IPF non-exec picks up shares, Hutchmed China director linked to sale

(Sharecast News) - International Personal Finance was among the companies on the list of director purchases on Thursday after a non-executive director spent more than £18k on shares.

Read more
12 Sep 2023 11:26

Hutchmed reports progress on two oncology fronts

(Sharecast News) - Hutchmed China reported significant strides in oncology research on Tuesday, completing patient enrollment for a bridging study of tazemetostat, and announcing pivotal results for the phase 3b clinical trial of savolitinib.

Read more
12 Sep 2023 10:26

IN BRIEF: Hutchmed China finalises patient enrolment for Tazemetostat

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Completes patient enrolment for bridging phase two study in China to evaluate the efficacy of cancer drug Tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma. Tazemetostat is approved by the US Food & Drug Administration for the treatment of advanced epithelioid sarcoma and R/R FL.

Read more
29 Aug 2023 13:38

Hutchmed tumour therapy candidate gets breakthrough designation

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced on Tuesday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to its investigational drug savolitinib.

Read more
12345678910

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.